DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Transendocardial Autologous Cells (hMSC or hMSC and hCSC) in Ischemic Heart Failure Trial (TAC-HFT II)

Information source: University of Miami
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Ischemic Left Ventricular Dysfunction; Myocardial Infarction

Intervention: Autologous hMSCs (Drug); Autologous Human C-Kit CSCs II (Drug); Placebo (Drug)

Phase: Phase 1/Phase 2

Status: Not yet recruiting

Sponsored by: Joshua M Hare

Official(s) and/or principal investigator(s):
Joshua M Hare, MD, Principal Investigator, Affiliation: ISCI / University of Miami Miller School of Medicine

Overall contact:
Joshua M Hare, MD, Phone: 305-243-5579, Email: Jhare@med.miami.edu

Summary

Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested. The randomized portion of the study will be conducted after a full review of the safety data from the pilot Phase by the Data safety monitoring board. Following the Pilot Phase of five (5) Fifty (50) patients scheduled to undergo cardiac catheterization and meeting all inclusion/exclusion criteria will be evaluated at baseline. Patients will be randomized in a 2: 2:1 ratio to one of three Treatment Strategies.

Clinical Details

Official title: A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Incidence of any treatment emergent serious adverse events (TE-SAEs)

Secondary outcome:

Treatment Emergent adverse event rates

Ectopic tissue formation

48-hour ambulatory electrocardiogram (ECG) recordings.

Hematology value changes post-catheterization

Urinalysis results changes post-catheterization

Clinical chemistry values post-catheterization

Pulmonary function

Serial troponin I values

Creatine kinase-MB (CK-MB) value changes post-catheterization

Post-cardiac catheterization echocardiogram.

Magnetic resonance imaging (MRI) measures of infarct scar size (ISS)

Echocardiographic measures of infarct scar size (ISS)

Left regional and global ventricular function.

Global ventricular function.

Tissue perfusion measured by MRI.

Peak oxygen consumption (Peak VO2) (by treadmill determination).

Six-minute walk test.

New York Heart Association (NYHA) functional class.

Minnesota Living with Heart Failure (MLHF) questionnaire.

Incidence of Major Adverse Cardiac Events (MACE)

Detailed description: A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction. A total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase. Patients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.

Eligibility

Minimum age: 21 Years. Maximum age: 89 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- In order to participate in this study, a patient MUST:

1. Be ≥ 21 and < 90 years of age. 2. Provide written informed consent. 3. Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI) as defined by the following: Screening MRI must show an area of akinesis, dyskinesis, or severe hypokinesis associated with evidence of myocardial scarring based on delayed hyperenhancement following gadolinium infusion. 4. Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensin-converting enzyme inhibition, the patient must have been on a stable dose of a clinically appropriate agent for 1 month. 5. Be a candidate for cardiac catheterization. 6. Have an ejection fraction ≤ 50% by gated blood pool scan, two-dimensional echocardiogram, cardiac MRI, or left ventriculogram within the prior six months and not in the setting of a recent ischemic event. Exclusion Criteria:

- In order to participate in this study, a patient MUST NOT:

1. Have a baseline glomerular filtration rate < 50 ml/min1. 73m2. 2. Have a known, serious radiographic contrast allergy. 3. Have a mechanical aortic valve or heart constrictive device. 4. Have a documented presence of aortic stenosis (aortic stenosis graded as ≥ +2 equivalent to an orifice area of 1. 5cm2 or less). 5. Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2). 6. Require coronary artery revascularization. Patients who require or undergo revascularization procedures should undergo these procedures a minimum of 3 months in advance of treatment within this study. In addition, patients who develop a need for revascularization following enrollment will be submitted for this therapy without delay. 7. Evidence of a life-threatening arrhythmia (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete heart block) or QTc interval > 550 ms on screening ECG. 8. AICD firing in the past 60 days prior to the procedure. 9. Have unstable angina within 2 weeks of the planned procedure. 10. Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation. 11. Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN. 12. Have a coagulopathy = (INR > 1. 3) not due to a reversible cause (i. e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR < 1. 3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment 13. Have known allergies to penicillin or streptomycin. 14. Have a contra-indication to performance of an MRI scan. 15. Be an organ transplant recipient. 16. Have a clinical history of malignancy within 5 years (i. e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma. 17. Have a non-cardiac condition that limits lifespan to < 1 year. 18. Have a history of drug or alcohol abuse within the past 24 months. 19. Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists. 20. Be serum positive for HIV, hepatitis BsAg or hepatitis C. 21. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial. 22. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.

Locations and Contacts

Joshua M Hare, MD, Phone: 305-243-5579, Email: Jhare@med.miami.edu

Additional Information

Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine

Starting date: March 2016
Last updated: July 16, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017